BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36662030)

  • 1. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
    Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
    Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
    Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
    BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
    Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
    Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment.
    Wang L; Jian Y; Yang G; Gao W; Wu Y; Zuo L
    Clin J Oncol Nurs; 2015 Feb; 19(1):E4-7. PubMed ID: 25689664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
    Jin F; Yang M; Chen Y; Jiang L; Liu L
    Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
    Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
    Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
    Terpos E; Politou M; Rahemtulla A
    J Cancer Res Clin Oncol; 2004 Oct; 130(10):623-5. PubMed ID: 15449188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
    Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
    Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
    Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory and clinical features of tumor lysis syndrome in children with non-Hodgkin lymphoma and evaluation of long-term renal functions in survivors.
    Bozkurt S; Genc DB; Vural S
    BMC Pediatr; 2024 Jan; 24(1):85. PubMed ID: 38297237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.
    Wu T; Liu D; Liu S; Xiao H; Xiong B; Zhou Y; Xiong Y; Cui Q; Wu J; Liu M; Liu H; Li Y; Wang M; Bao X; Li Y; Zhou F
    Ren Fail; 2024 Dec; 46(1):2356708. PubMed ID: 38803220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.
    Chang H; Lee SY; Tang TC
    Chang Gung Med J; 2011; 34(6 Suppl):70-5. PubMed ID: 22490464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluid overload and acute kidney injury in children with tumor lysis syndrome.
    Flood K; Rozmus J; Skippen P; Matsell DG; Mammen C
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29255. PubMed ID: 34302706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome.
    Biró E; Erdélyi D; Varga P; Sinkó M; Bartyik K; Kovács G; Ottóffy G; Vincze F; Szegedi I; Kiss C; Szabó T
    Pediatr Nephrol; 2023 Sep; 38(9):3117-3127. PubMed ID: 36943467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function.
    Ha SH; Park JH; Jang HR; Huh W; Lim HY; Kim YG; Kim DJ; Oh HY; Lee JE
    BMC Cancer; 2014 Dec; 14():906. PubMed ID: 25466872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration.
    Lee EJ; Jang HN; Cho HS; Bae E; Lee TW; Chang SH; Park DJ
    Ren Fail; 2018 Nov; 40(1):687-692. PubMed ID: 30741619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes mellitus does not affect the incidence of acute kidney injury after cardiac surgery; a nested case-control study.
    Moschopoulou M; Ampatzidou FC; Loutradis C; Boutou A; Koutsogiannidis CP; Drosos GE; Sarafidis PA
    J Nephrol; 2016 Dec; 29(6):835-845. PubMed ID: 26924544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of group LASSO regression based Bayesian networks in risk factors exploration and disease prediction for acute kidney injury in hospitalized patients with hematologic malignancies.
    Li Y; Chen X; Wang Y; Hu J; Shen Z; Ding X
    BMC Nephrol; 2020 May; 21(1):162. PubMed ID: 32370757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Renal Outcomes after Cisplatin Treatment.
    Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
    Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
    PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.